Tagged with Opinion

Opinion Drs David Higgins and Marco F Schmidt highlight the gap that exists between the abundant discussions around technological innovation in healthcare and implementation and why pharma needs to develop its own proprietary approaches to crunching ‘wide data’.   Data is the new oil, but biomedical data – despite its abundance…

Opinion In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr Neil Cashman highlights what the next steps in the process will be, why US FDA approval for the drug will pave the way for researchers working on second-generation AD medicines,…

USA Michael Ciarametaro, VP for Research at the US National Pharmaceutical Council (NPC), outlines issues surrounding the outdated Medicaid Best Price (MBP) and why there is a dire need for payment innovations to provide a way for US payers and manufacturers to share financial risk and ultimately ensure that patients can…

Opinion Holmusk’s Nawal Roy outlines why a cure for Alzheimer’s Disease is the “Holy Grail” of medicine today, the reasons for so many biotech companies failing to develop effective treatments for the disease, and why a more holistic systems approach may be the key to future success.   The ingenuity of…

Opinion As COVID-19 threatens to derail more than a decade’s worth of hard-won gains in the fight against malaria, Dr Benjamin Pretorius, managing director at ERADA Technology Alliance, warns that diversions of malaria resources and interruptions to prevention programmes may cost thousands of lives.   Malaria still takes the lives of…

Opinion In his latest piece, Brendan Shaw casts his eye over why those drawing up health policies need to start incorporating issues of industrial policy into their long-term planning in order to secure investments into the right kinds of R&D and to help build a more open and collaborative innovation ecosystem.…

Opinion Jessica Scott, Takeda’s head of R&D patient engagement, highlights how a better understanding of the value of patient engagement across the healthcare stakeholder spectrum will drive better health outcomes and why keeping an open and curious mindset is crucial in this endeavour.   By incorporating Patient Engagement (PE) into the…

Japan Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park explores new ways of virtual collaboration that make our lives easier while enabling us to maintain a culture of innovation and growth.   Are social distancing requirements causing the life science industry to return to an inward-looking culture of secrecy?…

Data New approaches to pharma sales: Marrying data analytics with the art of personal engagement   The lock-down impact for COVID-19 was stark, looking at available March data cuts from IQVIA which signal serious additional healthcare consequences beyond infected patients. A decline of 72% of in-person doctor visits, -70% Rx volume,…

USA Ulrich Neumann examines the debate around drug pricing in the US and why it is not going away any time soon.   Come senators, congressmen Please heed the call Don’t stand in the doorway Don’t block up the hall For he that gets hurt Will be he who has stalled”…

USA John G. Singer examines why technological solutions are not a quick fix to overcoming the COVID-19 crisis and how a systems shift is crucial to securing better health outcomes in the long-term.   Strategic failure begins when you turn things over to technologists.   “My 18-year-old daughter, Caroline, responded quickly…

Opinion In the wake of a spate of television advertisements for dietary supplements claiming to offer solutions to the COVID-19 crisis, regular PharmaBoardroom contributor Yacine Sellam argues for the need for a more robust regulatory framework in Algeria and even the creation of a unified FDA-style regulator to counter this threat…